Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03874884 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer

Study acronym: LuPARP
StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 2 of 2 sites
    v7
  2. Primary completion date: May 4, 2023 to May 2025v6 Show 4 more changesShow less
    • Enrollment target: 52 to 70
    • Study completion date: Dec 2023 to Jun 2026
    • Eligibility criteria expanded, about 36 words
    • Study description expanded, about 1 word
  3. Primary completion date changed from estimate of May 2023 to May 4, 2023v5
  4. Primary completion date: Apr 2022 to May 2023
    • Study completion date: Oct 2022 to Dec 2023
    v4
  5. Study sites: 1 to 2
    • Eligibility criteria shortened, about 43 words
    v3
  6. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Apr 2019 to Jul 9, 2019
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase 1 dose-escalation and dose-expansion study is designed to evaluate the safety and tolerability of olaparib in combination with 177Lutetium-Prostate Specific Membrane Antigen (177 Lu-PSMA) in patients with metastatic castration resistant prostate cancer (mCRPC).
Trial Details
NCT Number NCT03874884
Lead Sponsor Peter MacCallum Cancer Centre, Australia
Conditions
(from sponsor)		 Metastatic Castration Resistant Prostate Cancer (mCRPC)
Enrollment 70 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov